Complicated decisions on new migraine-prevention therapies

Lancet Neurol. 2019 Mar;18(3):221. doi: 10.1016/S1474-4422(19)30041-9. Epub 2019 Feb 12.

Author

The Lancet Neurology

PMID: 30784544
DOI: 10.1016/S1474-4422(19)30041-9

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / economics
Antibodies, Monoclonal, Humanized / therapeutic use
Calcitonin Gene-Related Peptide / immunology
Humans
Migraine Disorders / prevention & control*
Migraine Disorders / therapy*
United Kingdom

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
erenumab
Calcitonin Gene-Related Peptide